Rational study endpoint(s) for preoperative trials in pancreatic cancer: pathologic response rate, margin negative resection, overall survival or 'all of the above'?
Division of Cancer Medicine, The University of Texas M. D. Anderson Cancer Center, Houston, TX, USA.
Gauri R
GR
Varadhachary
Douglas B
DB
Evans
D000230:Adenocarcinoma / Q000628:therapy*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D021441:Carcinoma, Pancreatic Ductal / Q000628:therapy*; D005260:Female; D006801:Humans; D008297:Male; D009364:Neoplasm Recurrence, Local / Q000628:therapy*; D010190:Pancreatic Neoplasms / Q000628:therapy*